The ANSM communicates once again on cases of meningiomas reported when using cyproterone acetate, mainly in doses of 25 mg/day and more. The risk of meningioma increases with the increase in cumulative doses.

In an information point released on April 27 to health professionals , and taking into account the risk of meningioma linked to its use, the National Agency for the Safety of Medicines and Health Products (ANSM) recalls the principles of administration of cyproterone acetate: the use of the drug is contraindicated in patients with meningioma or a history of meningioma. Patients treated with cyproterone acetate must be monitored for monitoring and detection of meningiomas in accordance with clinical practice. If meningioma is diagnosed in a patient treated with this active ingredient, the treatment must be stopped definitively.

For major female female hirsutisms of non-tumor origin (idiopathic, polycystic ovary syndrome), when they graze seriously on psycho-affective and social life, cyproterone acetate at 50 mg is indicated when the use of drugs based on lower dose cyproterone or other treatment options has not obtained satisfactory results.

For the reduction of sexual impulses in paraphilies in combination with psychotherapeutic management, cyproterone acetate at 100 mg can be used when other treatments are deemed inappropriate.

The use of cyproterone acetate for the following indication remains unchanged: anti-Androgen palliative treatment of prostate cancer.

The prescription conditions and recommendations on monitoring users of cyproterone acetate issued in 2018 and 2019 remain unchanged. As a reminder, an information certificate must be signed each year by the patient and his prescribing doctor and given to the pharmacist for any issuance of these drugs.

Information point here: https://ansm.sante.fr/var/ansm_site/storage/original/application/688bb6917804fdba32c04cc267be4869.pdf